NPI registry status
Active
2026 NPPES data Gynecologic Oncology Physician NPI 1700449311 PA-C
Verify on CMS → Jessica Walchonski, PA-C
Gynecologic Oncology Physician in Los Angeles, California.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 1,364 in Gynecologic Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
167
Medicare Part D claims · 58 beneficiaries · Gynecologic Oncology Physician avg: 188
Generic prescribing
92%
generic claims · 8% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
83.7/100
▲ 1 pts above national avg 83.1 · Above neutral
Industry payments
$101.47
2 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2023
Compiled from official public sources by the PlainDoctor editorial team.
What the federal data shows
Jessica Walchonski, PA-C reported a CMS MIPS final score of 83.7/100 - above the 83.1 national average - and filed 167 Medicare Part D claims in 2023.
- 83.7/100
- MIPS score · +1 vs avg
- 167
- Part D claims, 2023
- 92%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Jessica Walchonski, PA-C's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure
84 42nd percentile higher than 42% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Jessica Walchonski, PA-C sits
This provider among gynecologic oncology physician peers
Across the 446 gynecologic oncology physician providers who report both Medicare Part D prescribing and a MIPS quality score, Jessica Walchonski, PA-C writes more Part D claims than 60% of them and scores higher on MIPS quality than 39% - placing this provider in the high-volume, lower-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one gynecologic oncology physician peer from a representative sample of 60; the gold marker is Jessica Walchonski, PA-C. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
✓
Board certification likely (heuristic, not verified)
Jessica Walchonski, PA-C practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Jessica Walchonski, PA-C?
Near national averagePrimary specialty
Gynecologic Oncology Physician
Medicare Part D claims
167 11% vs specialty avg
MIPS final score
83.7/100 0.6 pts vs avg
Specialty distribution in California
How Gynecologic Oncology Physician compares to other specialties among California providers
Medicare quality performance, MIPS
Jessica Walchonski, PA-C's 2023 MIPS final score plotted against the Gynecologic Oncology Physician national average
- MIPS Final Score
- 83.7/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Gynecologic Oncology Physician) - 83.7/100 vs national avg 83.1
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Jessica Walchonski, PA-C appears in the CMS NPPES registry as a Gynecologic Oncology Physician provider holding PA-C credentials at 200 UCLA MEDICAL PLZ STE 220, Los Angeles, CA, 90095, with a listed phone of (310) 794-7274. NPI 1700449311 was issued on 04/18/2019.
Medicare Part D records for calendar year 2023 show 167 prescription claims written by this provider, covering 58 Medicare beneficiaries and totaling roughly $97K in drug spend, split 8% brand-name and 92% generic by claim count. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 83.7/100 for the 2023 performance year (Quality 83.5, Cost 51.1), compared with the national average of 83.1.
Gynecologic Oncology Physician is a narrow specialty nationwide, with 1,364 enrolled providers across 49 states and an average of 188 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1700449311 |
|---|---|
| Specialty | Gynecologic Oncology Physician |
| Credentials | PA-C |
| Gender | Female |
| NPI Issued | 04/18/2019 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
83.6828
Final Score
Avg: 83.1
83.5373
Quality
51.137
Cost
100
Promoting Interoperability
Reporting: Group practice
Hospital and facility affiliations
Facilities where Jessica Walchonski, PA-C bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Regents OF The University OF California
Los Angeles, CA
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Jessica Walchonski, PA-C. Source: openpaymentsdata.cms.gov.
Total received
$101
Largest payer
GlaxoSmithKline, LLC.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - California MBC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 - they are NOT specific to Jessica Walchonski, PA-C. To verify Jessica Walchonski, PA-C's current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases
MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Generic-heavy
Jessica Walchonski, PA-C - brand share 8.0%
Gynecologic Oncology Physician average
8% brand-name claims vs 92% generic, on 167 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
167
Total Claims
$97K
Total Drug Cost
58
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 235
- Total Day Supply
- 5,424
- Brand vs Generic
- 8% brand / 92% generic
- Brand Drug Cost
- $93K
- Generic Drug Cost
- $4K
- Antibiotic Claims
- 18
Patient Demographics
- Average Patient Age
- 72.3 years
- Avg HCC Risk Score
- 2.12
- Gender Split
- 100% female / 0% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Jessica Walchonski, PA-C prescribes most
Top Medicare Part D drugs by claim count, 2023
- Ondansetron Hcl
Ondansetron Hcl
20 claims
- Prochlorperazine M…
Prochlorperazine Maleate
15 claims
- Lorazepam
Lorazepam
14 claims
- Dexamethasone
Dexamethasone
11 claims
- Letrozole
Letrozole
11 claims
| Drug | Claims |
|---|---|
| Ondansetron Hcl | 20 |
| Prochlorperazine Maleate | 15 |
| Lorazepam | 14 |
| Dexamethasone | 11 |
| Letrozole | 11 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Gynecologic Oncology Physician Overview
How Jessica Walchonski, PA-C fits within the Gynecologic Oncology Physician landscape nationally.
1,364
Gynecologic Oncology Physician Providers in US
49
States with Gynecologic Oncology Physician
188
Avg Claims per Provider
Jessica Walchonski, PA-C's 167 claims are below the specialty average of 188.
Nearby Gynecologic Oncology Physician Providers in California
Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as Walchonski.
Dr. Lisa Abaid
M.D., M.P.H.
Newport Beach, CA
Dr. Alireza Abidi
M.D.
Sacramento, CA
Dr. Federico Alva
M.D.
Northridge, CA
Dr. Edwin Alvarez
M.D.
Sacramento, CA
Dr. Kristen Anderson
M.D., PH.D.
Moreno Valley, CA
Compare Gynecologic Oncology Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the California medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Gynecologic Oncology Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
How to Find a Doctor
Step-by-step guide to choosing a provider
Verify Credentials
Check NPI, board certification & license status
Medical Specialties Explained
Who treats what and how specialties differ
Understanding Medicare Claims Data
What prescribing data reveals about a provider
In-Network vs Out-of-Network
How insurance networks affect your costs
Telehealth Guide
Virtual care options and coverage in 2026
Explore California
Frequently Asked Questions
What is Jessica Walchonski, PA-C's specialty? ▼
Jessica Walchonski, PA-C specializes in Gynecologic Oncology Physician and practices in Los Angeles, California. Credentials: PA-C.
How much does Jessica Walchonski, PA-C prescribe under Medicare Part D? ▼
In 2023, Jessica Walchonski, PA-C wrote 167 Medicare Part D claims totaling $97K in drug costs for 58 beneficiaries.
What is Jessica Walchonski, PA-C's Medicare quality score? ▼
Jessica Walchonski, PA-C has a CMS MIPS Final Score of 83.7/100 (Quality: 83.5, Cost: 51.1). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Jessica Walchonski, PA-C located? ▼
Jessica Walchonski, PA-C is located at 200 UCLA MEDICAL PLZ STE 220, Los Angeles, CA, 90095. Phone: (310) 794-7274.
What is Jessica Walchonski, PA-C's NPI number? ▼
Jessica Walchonski, PA-C's National Provider Identifier (NPI) is 1700449311, issued on 04/18/2019.
Does Jessica Walchonski, PA-C prescribe more brand-name or generic drugs? ▼
Jessica Walchonski, PA-C's prescribing is 8% brand-name and 92% generic drugs by claim count, with $93K in brand drug costs.
How many Gynecologic Oncology Physician providers are there in the US? ▼
There are 1,364 Gynecologic Oncology Physician providers across 49 states in the US. The average Gynecologic Oncology Physician provider writes 188 Medicare Part D claims per year.
What drugs does Jessica Walchonski, PA-C prescribe most often? ▼
Based on 2023 Medicare Part D data, Jessica Walchonski, PA-C's most frequently prescribed drugs include Ondansetron Hcl, Prochlorperazine Maleate, Lorazepam. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Jessica Walchonski, PA-C accept Medicare? ▼
Jessica Walchonski, PA-C appears in CMS Medicare data with 167 Part D claims and 58 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Jessica Walchonski, PA-C's credentials? ▼
Jessica Walchonski, PA-C's NPI is 1700449311 with credentials PA-C. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Compiled from official public sources by the PlainDoctor editorial team.
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.